Bayer wins FDA approval for new stroke drug with lower bleeding risk
The FDA has approved Bayer’s new drug, the first in a class aimed at preventing blood clots without added bleeding risk. This could shift treatment standards for stroke prevention in pharma and healthcare. Watch for uptake and payer decisions.
Palantir pressed UK minister to expand AI access to NHS GP records, raising data trust issues
Palantir lobbied a UK health minister to include sensitive GP records in its NHS data platform, despite government promises to exclude them. This move raises concerns for healthcare leaders about data privacy, AI governance and patient trust. Watch for government decisions on contract scope and future suppliers.
FDA warns on rare eye risk linked to GLP-1 obesity and diabetes drugs
The FDA has warned that GLP-1 drugs may increase the risk of a rare eye condition. Pharma and biotech leaders face heightened regulatory scrutiny and potential market impact. Companies may need to review safety data and update risk disclosures.
Tencent AI chief warns of biological risks from open AI models
Tencent’s AI chief said AI models could soon cause harm in biology, not just cybersecurity. This raises new risk management questions for pharma, healthcare and regulated sectors. Executives should follow the debate on open versus closed AI models.
AI-driven drug research disappoints again in pharma sector
A promising AI technology aimed at accelerating drug research has failed to deliver, according to STAT. This setback raises questions about the reliability of AI in regulated biotech and pharma industries. Firms should review AI risk and validation processes.
Novartis drug lowers risk marker but fails to cut heart attack rates
Novartis reported that its drug reduced a cardiovascular risk marker but did not lower heart attack or stroke rates. This challenges assumptions in cardiovascular drug development. Pharma leaders may need to reconsider biomarker-based strategies.
BIO challenges US Medicare pilot linking drug prices to peer nations
BIO is joining a legal challenge to a US Medicare pilot that ties drug prices to those in peer countries. This move could affect how pharma firms set prices in the US. Senior leaders should watch for shifts in pricing policy and legal precedent.
Democrats’ midterm gains may ease pressure on US hospitals
Democrats are expected to prioritise reversing Medicaid cuts and expanding insurance coverage, according to STAT. This could improve funding stability for healthcare providers. Hospital leaders should watch for regulatory shifts affecting reimbursement and access.
States file new lawsuit to block Trump Medicaid work requirements
States have launched another lawsuit against the Trump administration over Medicaid work requirements, according to STAT. The move signals ongoing legal risk for health insurers and care providers reliant on Medicaid contracts. Watch for further court rulings on implementation.
CMS expands power to revoke Medicare billing for owner misconduct
US regulators can now revoke Medicare billing rights from providers and parent firms that breach federal rules. This raises compliance risks for healthcare groups and investors. Boards should review ownership structures and risk controls.
US regulators cut Medicare payments for doctors in 2027
US regulators have finalised a reduction in Medicare payments to doctors for 2027, according to Healthcare Dive. Healthcare providers warn the cuts could further destabilise the sector. Senior executives should assess how pay changes may affect provider networks and service delivery.
Medicare to restrict third-party remote monitoring until 2029
Medicare will bar hospitals from using third parties for remote patient monitoring services, despite opposition. This move could reshape how providers deliver digital health support. Healthcare leaders should assess the impact on care delivery models and vendor contracts.
Mayo Clinic Platform launches AI tool for clinical decision support
Mayo Clinic Platform has launched an AI chatbot to help clinicians with diagnosis and care decisions in over 35 specialties. This move could influence how healthcare providers use AI in daily practice. Providers should assess integration and impact on clinical workflows.
US finalises Medicare cuts to 340B drug payments, plans site-neutral pricing
US regulators have finalised a rule to cut payments for drugs under the 340B programme and introduce site-neutral payments in 2027. This move affects hospital revenues and drug pricing models. Healthcare leaders must assess impacts on margins and contracting.
US drops two No Surprises Act arbitrators over performance concerns
The US government has ended contracts with two groups handling surprise medical bill disputes, citing poor performance. This move could affect how insurers and providers resolve payment conflicts. Stakeholders should monitor for delays or changes in arbitration outcomes.
PhRMA spends $59 million on search ads to shape drug pricing debate
PhRMA invested $59 million in search advertising over seven years to influence US views on drug pricing, according to STAT. This scale of digital spend signals the importance of online opinion shaping for pharma brands. CMOs should assess how such tactics affect reputation and policy risk.
Novartis reports seven tumour cases in Zolgensma-treated children
Novartis has reported seven new tumour cases in children treated with its spinal muscular atrophy gene therapy. This raises safety questions for pharma leaders monitoring gene therapy risks. Firms should track regulatory responses and patient safety updates.
Medicare pays nearly $1,000 more per stay at private equity-owned hospices
Medicare spends almost $1,000 more per stay at hospices owned by private equity firms, according to researchers. This raises questions about financial risk and regulatory scrutiny for healthcare providers. Leaders should watch for further investigation and policy response.
Ultragenyx cuts 20% of staff after rare disease drug setbacks
Ultragenyx is cutting about 20% of its workforce after stopping work on two rare disease drugs. The move signals cost pressure and shifting priorities for pharma leaders. Companies may need to review pipeline risks and workforce plans.
Hackers raise temperatures at French blood banks in cyber-attack
Hackers accessed control systems at three French blood bank cold stores, raising temperatures to dangerous levels, according to the national blood service. The incident shows the vulnerability of critical infrastructure in healthcare and other regulated sectors. Firms should review cyber risk in supply chains.